A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 763-768

  Song, Hong Suk ^a   Do, Young Rok ^a   Chang, Heung Moon ^b   Ryu, Min Hee ^b   Lee, Kyung Hee ^c   Kim, Yeul Hong ^d   Hong, Dae Sik ^e   Cho, Jae Yong ^f   Lee, Kyoung Eun ^g   Kim, Si Young ^h  

^a Dongsan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Yeungnam University Hospital   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Soonchunhyang University College of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Mokdong Hospital   (South Korea)

^h Kyung Hee University College of Medicine   (South Korea)

Author keywords

Capecitabine; Chemotherapy; Gemcitabine; Pancreatic cancer

Indexed keywords

CAPECITABINE; GEMCITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PATIENT COMPLIANCE; SURVIVAL ANALYSIS;

EID: 49749126800     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0661-y     Document Type: Article

References (24)

1. DM Kelly IS Benjamin 1995 Pancreatic carcinoma Ann Oncol 6 19 28
2. JE Niederhuber MF Brennan HR Menck 1995 The national cancer database reports on pancreatic cancer Cancer 76 1671 1677
3. Korean National Cancer Center (2001) Korean central cancer registry 22nd annual report. Available from http://www.ncc.re.kr
4. RH Hawes Q Xiong I Waxman KJ Chang DB Evans JL Abbruzzese 2000 A multispecialty approach to the diagnosis and management of pancreatic cancer Am J Gastroenterol 95 17 31
5. HA III Burris MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413
6. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori N Shimma I Umeda H Ishitsuka 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281
7. J Schüller J Cassidy E Dumont B Roos S Durston L Banken M Utoh K Mori E Weidekamm B Reigner 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 291 297
8. J Cassidy C Twelves E van Cutsem P Hoff E Bajetta M Boyer R Bugat U Burger A Garin U Graeven J McKendrick J Maroun J Marshall B Osterwalder G Pérez-Manga R Rosso P Rougier RL Schilsky on behalf of the Capecitabine Colorectal Cancer Study Group 2002 First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 566 575
9. TH Cartwright A Cohn JA Varkey YM Chen TP Szatrowski JV Cox JJ Schulz 2002 Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 160 164
10. V Hess M Salzberg M Borner R Morant AD Roth C Ludwig R Herrmann 2003 Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial J Clin Oncol 21 66 68
11. GP Stathopoulos K Syrigos A Polyzos G Fountzilas SK Rigatos N Ziras A Potamiannou I Tsiakopoulos N Androulakis G Aravantinos A Athanasiadis P Papakotoulas V Georgoulias 2004 Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study Ann Oncol 15 224 229
12. RL Schilsky D Bretucci NJ Vogelzang HL Kindler MJ Ratain 2002 Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer J Clin Oncol 20 582 587
13. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
14. LG Ensign EA Gehan DS Kamen PF Thall 1994 An optimal three-stage design for phase II clinical trials Stat Med 13 1727 1736
15. ES Casper MR Green DP Kelsen RT Heelan TD Brown CD Flombaum B Trochanowski PG Tarassoff 1994 Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas Invest New Drugs 12 29 34
16. M Hidalgo D Castellano L Paz-Ares C Gravalos M Diaz-Puente R Hitt S Alonso H Cortes-Funes 1999 Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer J Clin Oncol 17 585 592
17. H Oettle M Arning U Pelzer D Arnold C Stroszczynski J Langrehr P Reitzig M Kindler J Herrenberger R Musch FW Korsten D Huhn H Riess 2000 A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer Ann Oncol 11 1267 1272
18. Q Ren V Kao JL Germ 1998 Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2-deoxyuridine in HT-29 colon cancer cells Clin Cancer Res 4 2811 2818
19. D Cunningham I Chau D Stocken C Davies J Dunn J Valle D Smith W Steward P Harper J Neoptomos 2005 Phase III randomised comparison of gemcitabine (GFM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 3 supplement 12 PS12)
20. W Scheithauer B Schull H Ulrich-Pur K Schmid M Raderer K Haider W Kwasny D Depisch B Schneeweiss F Lang GV Korneck 2003 Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann Oncol 14 97 104
21. M Tempero W Plunkett V van Ruiz Haperen J Hainsworth H Hochster R Lenzi J Abbruzzese 2003 Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 3402 3408
22. K Nakamura T Yamaguchi T Ishihara A Kobayashi H Tadenuma K Sudo H Kato H Saisho 2005 Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br J Cancer 92 2134 2139
23. SS Ng MS Tsao T Nicklee DW Hedley 2002 Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 777 783
24. MJ Moore D Glodstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K ing G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar National Cancer Institute of Canada Clinical Trials Group 2007 Erlotinib plus gemcitabine compared gemcitabine alone in patients with advanced pancreatic cancer: a III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 20 1960 1966